Illumina Selects BioDiscovery's NxClinical Software for Data Visualization & Interpretation for its CytoSeq ™ assay, an NGS-based Solution for Detection of Genomic Events

BioDiscovery Inc. and Illumina Inc. have collaborated to provide BioDiscovery's NxClinical software as the secondary data analysis and management tool for Illumina's CytoSeq™ assay, providing customers with a powerful tool for studying CNVs, AOH, and SNVs.

El Segundo, CA (PRWEB) May 10, 2016

BioDiscovery, Inc., a leader in innovative genomic data analysis software solutions announced today a collaborative agreement with Illumina Inc. ILMN to provide BioDiscovery's NxClinical software as the secondary data analysis and management tool for Illumina's CytoSeq™ assay. The NxClinical software will be offered with the CytoSeq product to provide an easy-to-use interactive tool for visualization and interpretation of genomic events.

Illumina's NGS based CytoSeq assay will extend beyond traditional microarray-based cytogenetics assays for detection of copy number variation (CNV) and absence of heterozygosity (AOH), but also adds the ability to identify single nucleotide variation (SNV), all in a single assay. Coupled with BioDiscovery's NxClinical software for analysis and interpretation of genomic events, the new solution will provide customers with a powerful and cost effective research tool for studying CNVs, AOH, and mutations in genetic disorders.

"We are extremely pleased to be working with Illumina to provide an analytical and data management software for CytoSeq," said Dr. Soheil Shams, President of BioDiscovery. "Our expertise in integrated genomic data analysis and visualization software perfectly complements Illumina's robust and advanced technologies for sequencing and microarrays. NxClinical was designed to provide reliability and consistency in the analysis and reporting of genomic events and encompasses many automated features that increase efficiency and eliminate repetitive tasks. The software's ability to handle different types of data such as CNV, allelic events, and sequence variants makes it an ideal tool for CytoSeq."

"We are proud to partner with BioDiscovery and are excited to offer NxClinical software with this product. We feel this collaboration offers the market a transformational research tool for cytogenetic and molecular genetic applications," said Rich Shippy, Senior Director of Product Marketing at Illumina.

The two companies are working together to ensure customers will have a comprehensive solution for analysis, visualization, and interpretation of genomic events. The NxClinical software will directly read CytoSeq results to process sample data and provide results in an easy-to-use, powerful, and interactive interface.

About BioDiscovery, Inc.
BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. The company's mission is to enable scientists to eliminate disease and suffering through application of computational technologies and translating these findings directly and rapidly to clinical use. From its inception in 1997, BioDiscovery has been an innovative leader in the genomics field having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. BioDiscovery's passion to make a difference has further extended the company's reach into creating the most comprehensive enterprise-wide system enabling research findings to translate into clinical applications and make direct impact on patient care. For more information, visit http://www.biodiscovery.com.

Please note the following:
The BioDiscovery software tools referenced are designed to assist clinical researchers and are not intended as primary diagnostic tools. It is each lab's responsibility to use the software in accordance with internal policies as well as in compliance with applicable regulations.
Contact information:
BioDiscovery, Inc.

Shalini Verma
MarCom Manager
+1 310-414-8100
MarCom(at)biodiscovery.com
Illumina, Inc.

Investors:
Rebecca Chambers, 858-255-5243
ir(at)illumina.com
or
Media:
Tina Amirkiai, 858-882-6822
pr(at)illumina.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2016/05/prweb13402640.htm